8/17/2019 Cheklist Malignancy Estella http://slidepdf.com/reader/full/cheklist-malignancy-estella 1/25 Guidelines Pediatric Oncology Center, for the Estella Children’s Cancer Clinics Translated and paraphrased from the VUmc Pediatric Oncology- Hematology epartment By Prof Anjo JP Veerman, October 2014 !"T#OUCT!O" The care for patients with cancer is comple! "any professionals play a role! The resi#ents are the $in%pin of care on the war#! These %&i#elines are for all in'ol'e#, b&t especially for the #octors in the (rst line of treatment of chil#hoo# cancer) the resi#ents! B&t of co&rse these %&i#elines ha'e to be s&pporte# an# acti'ate# an# intro#&ce# to all new resi#ents on the war#! *itho&t learnin% these r&les by heart no resi#ent sho&l# be allowe# on the war#! iagnostic Phase *hen a chil# is a#mitte# with a +pres&me##ia%nosis of mali%nancy, of co&rse the whole family will be f&ll of sorrow! *hat will happen- .or many people mali%nancy is a #eath warrant! /o it is important for the #octors an# n&rses to ha'e intense an# repeate# inter'iews with the parents an# sometimes %ran#parents or other family members ! .irst inter'iews may be &ite short, to inform the family abo&t the imme#iate proce#&res! ater on, the net #ay for instance, more elaborate information may ta$e half an ho&r, an# in the net few #ays an inter'iew of maybe 10 min&tes is eno&%h! "&ch #epen#s on the wishes of the family in this respect! B&t #aily contact will help to %i'e the family tr&st in the pe#iatric oncolo%y team! planation will be re&ire# abo&t the #ia%nostic meas&res to be ta$en, an# the propose# treatment, as well as the chances of c&re! 3f a #ia%nosis of mali%nancy is ma#e, sta%in% is important for the correct treatment protocol an# for the pro%nosis! The chec$list new patients will help to ma$e a #ia%nostic plan! Pre-Treatment Phase 3f the eact #ia%nosis is certain an# the sta%e of the #isease is ascertaine#, the treatment plan can be set &p! .or soli# t&mors, the plan has to be #isc&sse# in the T&mor Boar#, with the rele'ant other specialists! et to the pe#iatric oncolo%ist an# responsible resi#ent, that will always be the ra#iolo%ist, most often the pe#iatric s&r%eon, or ophthalmolo%ist an# a pe#iatric oncolo%y n&rse as well as social wor$er an# psycholo%ist sho&l# be present! The family will be informe# abo&t the treatment plan! This will entail #isc&ssin% the #ia%nosis, the treatment, the pro%nosis! Also si#e e5ects #&rin% treatment an# a short mention of potential late e5ects sho&l# be part of the #isc&ssions! A chec$list with all areas to be co'ere# may help to be complete, an# is sometimes afterwar#s &sef&l if #isc&ssion6let alone liti%ation6 occ&rs! 7hil#ren sho&l# be informe# accor#in% to their psycholo%ical a%e! The yo&n%er, the more important is what is %oin% to happen imme#iately! The ol#er the patient, the more Pa%e 1
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Guidelines Pediatric Oncology Center, for the Estella Children’s CancerClinics
Translated and paraphrased from the VUmc Pediatric Oncology-Hematology epartment
By Prof Anjo JP Veerman, October 2014
!"T#O UCT!O"
The care for patients with cancer is comple ! "any professionals play a role! Theresi#ents are the $in%pin of care on the war#! These %&i#elines are for allin'ol'e#, b&t especially for the #octors in the (rst line of treatment of chil#hoo#cancer) the resi#ents! B&t of co&rse these %&i#elines ha'e to be s&pporte# an#acti'ate# an# intro#&ce# to all new resi#ents on the war#! *itho&t learnin% theser&les by heart no resi#ent sho&l# be allowe# on the war#!
iagnostic Phase
*hen a chil# is a#mitte# with a +pres&me# #ia%nosis of mali%nancy, of co&rsethe whole family will be f&ll of sorrow! *hat will happen- .or many peoplemali%nancy is a #eath warrant! /o it is important for the #octors an# n&rses toha'e intense an# repeate# inter'iews with the parents an# sometimes%ran#parents or other family members ! .irst inter'iews may be &ite short, toinform the family abo&t the imme#iate proce#&res! ater on, the ne t #ay forinstance, more elaborate information may ta$e half an ho&r, an# in the ne t few#ays an inter'iew of maybe 10 min&tes is eno&%h! "&ch #epen#s on the wishes
of the family in this respect! B&t #aily contact will help to %i'e the family tr&st inthe pe#iatric oncolo%y team! planation will be re &ire# abo&t the #ia%nosticmeas&res to be ta$en, an# the propose# treatment, as well as the chances ofc&re! 3f a #ia%nosis of mali%nancy is ma#e, sta%in% is important for the correcttreatment protocol an# for the pro%nosis! The chec$list new patients will help toma$e a #ia%nostic plan!
Pre-Treatment Phase
3f the e act #ia%nosis is certain an# the sta%e of the #isease is ascertaine#, thetreatment plan can be set &p! .or soli# t&mors, the plan has to be #isc&sse# inthe T&mor Boar#, with the rele'ant other specialists! e t to the pe#iatriconcolo%ist an# responsible resi#ent, that will always be the ra#iolo%ist, mostoften the pe#iatric s&r%eon, or ophthalmolo%ist an# a pe#iatric oncolo%y n&rse aswell as social wor$er an# psycholo%ist sho&l# be present!
The family will be informe# abo&t the treatment plan! This will entail #isc&ssin%the #ia%nosis, the treatment, the pro%nosis! Also si#e e5ects #&rin% treatmentan# a short mention of potential late e5ects sho&l# be part of the #isc&ssions! Achec$list with all areas to be co'ere# may help to be complete, an# is sometimesafterwar#s &sef&l if #isc&ssion6let alone liti%ation6 occ&rs! 7hil#ren sho&l# be
informe# accor#in% to their psycholo%ical a%e! The yo&n%er, the more importantis what is %oin% to happen imme#iately! The ol#er the patient, the more
perspecti'e can be %i'en for the whole treatment! 8emember always thatlistenin% is more important e'en than tal$in%! 8emember why we ha'e two earsan# only one mo&th! Than it is also time to inform the referrin% #octor, be itanother pe#iatrician or a %eneral practitioner! 8e%istration of the new patient isan important tas$ too! 3f a research project is part of the treatment, informe#consent sho&l# be obtaine# from the parents, an# if possible form the chil#!
uring treatment
.or each treatment protocol not only the 9ow sheet sho&l# be a'ailable, b&t alsothe %&i#elines to that speci(c protocol! The resi#ent in char%e sho&l# st&#y these%&i#elines an# especially the parts rele'ant to the treatment phase he:she isresponsible for! .or each patient a c&m&lati'e s&mmary sho&l# be ma#e e'ery.ri#ay, so that the team that is in char%e #&rin% o5 ho&rs at ni%ht an# in thewee$en# can see in a short time all the rele'ant #ata! /pecial care has to beta$en for hy%iene, especially han# washin% an# cleanin% of instr&ments+stethoscope; an# of isolatin% the patient if he:she has low white co&nts +re'erseisolation as well as when a patient #e'elops an infection +isolation ! Oftentimesisolation an# re'erse isolation %o han#6in6han#! 3f the patient is #ischar%e# as&mmary of the clinical perio# sho&l# be ma#e an# #istrib&te# to the secretary of the pe#iatric oncolo%y center an# to the o&tpatient clinic,, an# where rele'ant tothe referrin% #octor!
$ollo%-up
<&rin% treatment it is important that the family is instr&cte# when an# where to
come bac$ for chec$s an#:or treatment! Also here, information sho&l# be %i'en tothe secretary:#ata mana%er! 3t is important to instr&ct the family what to #o if thechil# falls ill or #e'elops fe'er! "eas&res to be ta$en may #epen# on where thepatient li'es, at home far away, closer by or in the %&est ho&se! Also important ishow they tra'el) #o they ha'e a car, or are they #epen#ent &pon p&blic transport!After treatment is (nishe# it is necessary that families come bac$ for chec$6&p onlate e5ects, an# to ass&re that there is no relapse! This can be #one by simplehistory ta$in%, physical e amination an# basic laboratory wor$! 3n 3n#onesiacompliance with treatment is often a problem), ref&sal of treatment +parents ta$ethe chil# home before treatment , aban#onment +patients #rop o&t #&rin%treatment, or fail to a#here to protocol for more than a few wee$s as well as lossto follow6&p +no show after treatment is complete# ! 3n all these cases it is of&tmost importance to ha'e a means of reachin% the families! This is best #one bymobile phone, sms, b&t if nee#e# ho&se 'isit sho&l# be consi#ere#! The =P orlocal pe#iatrician may be as$e# to help in these matters!
7ar#iolo%y 7ar#iac /= if protocol containsanthracyclines
A&#iolo%y >earin% test if protocol contains platin&m
#r&%sPsycholo%y All families, +an# chec$ for researchproject
/&r%ery p front +; in all patients with soli#t&mors
&tritionist All patients who start on chemotherapy!nformation
.amily 3nfo stella 7linic, .low sheet protocol,informe# consent form for researchprojects an# for #ata collection, infoteam names
7ollea%&es /&mmary of #ia%nosis an# protocolE0tra1asation of cytostatic drugs2
To be complete# from the Cwaliteits et!
(upporti1e Care
Hydration ) =oal) to ass&re a#e &ate 9&i# inta$e! Often chil#ren arri'e athospital alrea#y a little #ehy#rate#! 8o&te) Oral:naso%astric t&be, intra'eno&s!"a imally 2,000 ml:m2:#ay! 3f i') a7l 0!4GI, =l&cose 2!GI with a##ition of C7l162 m"ol:#ay ! o C7l if t&mor lysis is possible!
Hyper-hydration+ =oal is to pro'i#e forced diuresis , to pre'ent $i#ney an#bla##er #ama%e by to ic pro#&cts from t&mor cells, or from cytostatic #r&%s+"ethotre ate, 7isplatin, cyclophosphami#e ! (o the inta3e is not the goal,/ut the rapid e0cretion2 Therefore precise 9&i# balance is essential! As soon asthe &rine pro#&ction becomes less, the inta$e sho&l# be lessene# too, otherwisethe patient will %et e#ema an# car#iac fail&re! <i&retics may be &se# to stim&latethe #i&resis e cept with 7isplatin!
2! Possi/le tumor lysis syndromea! ewly #ia%nose# hematolo%ical mali%nancy, ne&roblastomab! 7hec$ 9&i# balance e'ery K ho&rs! 3nstr&ct n&rses to call
imme#iately if &rine pro#&ction falls!c! Bo#y wei%ht at least #aily to chec$ for 9&i# o'erloa#!#! Physical e amination at start e'ery shift to chec$ for e#ema an#
2! Total 'ol&me H,000 ml:m2:#ay, ma imally G,000ml:#ayH! 3ntra'eno&sly a7l 0!4GI %l&cose 2!GID C7l a##ition 162""ol:$%:#ay4! 3n case of t&mor lysis prophyla is +hyperhy#ration no a##ition of C, 7a
an# P, beca&se these will be release# by #isinte%ratin% mali%nant cells,an# may be retaine# by $i#ney f&nction problems;
Cisplatin, Car/oplatin
1! /tart hy#ration 4 h before start platin&m compo&n#2! Post6hy#ration 24h after stop platin&m compo&n#H! 7isplatin is contra6in#ication for &se of #i&retics since nephroto icity may
increase, in this case mannitol is &se# to achie'e force# #i&resis +seebelow ! 3f cisplatin is %i'en as 24 ho&r contin&o&s inf&sion, mannitol is notnee#e#!
4! 8enal t&b&lar #ama%e may res< in loss of electrolytes! Therefore chec$ser&m 7a, P, a, C an# "% an# of co&rse &rea an# creatinine at least once#aily, before an# after the chemo co&rse!
G! After a co&rse of 7isplatin, prescribe "% s&ppletion +for instance "% 7itrateK0m%:$%:#ay in three #oses !
Cyclophosphamide 56788mg m9 course:, !phosphamide
1! Pre6hy#ration H ho&rs2! Post6hy#ration 24 ho&rsH! " / A is %i'en to pre'ent hemorrha%ic cystitis) #osa%e same #ose in
milli%rams as 7yclo:3fosfami#e pl&s H0I of this #osa%e as a p&sh beforestart! /o if for instance cyclophosphami#e #osa%e is 1!000m%:m2, then" / A p&sh is %i'en HG0m%:m2 before start 7yclophosphami#e an#followe# by 1,000m%:m2:#ay contin&o&s inf&sion #&rin% 24 ho&rs!Alternati'ely, instea# of contin&o&s inf&sion, " / A may be %i'en in H#i'i#e# #osa%es per #ay as bol&s inf&sion!
4! 3f 7yclo:3fosfami#e is %i'en on se'eral consec&ti'e #ays, the loa#in% #oseof H0I m&st be omitte# on secon# an# followin% #ays!
G! aboratory chec$ &rine e'ery portion 'oi#e# for erythrocytes +if &sin%stic$s be aware that the $etone reaction will also be false positi'e; ! 3fmicroscopic hemat&ria is #e'elopin% contin&e " / A an# hyperhy#ration!3f 'ery painf&l an# clots of bloo# are obser'e# in the &rine, there may bein#ication to rinse the bla##er with a sol&tion of " / A!
T; 56<88mg m9:
1! Pre6hy#ration 4h before a#ministration of "T2! /tart al$aliniEation also 4 h before "T to $eep p> of &rine L b&t not
more than p> M!G; Prescribe a>7OH +4!2I 120ml:m2:#ay contin&o&s i'!3ncrease by 20I if &rine p> FL!0! "eas&re &rine p> at e'ery portion &rine'oi#e#!
H! Post6hy#ration &ntil 24h after (nishin% "T inf&sion +b&t see also Aprotocol
4! e&co'orin) life sa'in%; 3f #elaye# or for%otten, #eep bone marrow aplasiaan# se'ere m&cositis will #e'elop! /ee below
annitol
• 3n#ication) cisplatin, since #i&retics are contra6in#icate#, mannitol is &se#for force# #i&resis
• 3f cisplatin is %i'en as 24h contin&o&s inf&sion, mannitol can be omitte#!• 3f the protocol #oes not prescribe e act &se of mannitol &se "annitol 20I
+200m%:ml an# prescribe L!Gml:m2:ho&r! /tart 4 h before start cisplatinan# stop Kh after stop cisplatin!
'euco1orin
• /ee respecti'e protocol for #etails!• ssential to pre'ent si#e e5ects of "T , so start the =rst dose e0actly
on time>>>• 7hec$ creatinine before start "T an# 24h after start "T ) if 2 initial
'al&e at 24h after start "T ) #o&ble the #ose of e&co'orin!
Eye drops
• To pre'ent chemical conj&ncti'itis• 3n#ication) >i%h <ose Ara67 can res< in chemical conj&ncti'itis by
e cretion of A8A67 in tears 9&i#! Also the cornea may be a5ecte#! 8es< ispain an# photophobia an# re# conj&ncti'ae!
• 3f still pain a## #iclofenac 0!1I eye #rops +H## 2 #rops each eye• Literature: Matteucci et al.: Topical prophylaxis of conjunctivitis induced by
high dose Cytosine Arabinoside. Haematologica !!"#$%: &' &(
Progestati1es and $ertility
*im+ to s&ppress menstr&ation to pre'ent bloo# loss an# &nnecessary bloo#transf&sions
edication+
• 7ons< %ynecolo%ist is a %oo# i#ea! Pro'era N pro%esterone! Prescribe 1## Gm%, an# increase to 10 m% if still
&terine bloo# loss! <isa#'anta%e) it is not contracepti'e; "icro%ynon or similar) prescribe #ayly, witho&t the &s&al stoppin% of G
#ays beca&se then with#rawal blee# will occ&r, which we wo&l# li$e topre'ent, especially if there is also thrombocytopenia; <isa#'anta%e isincrease# ris$ of thrombosis, so combination with 6Aspara%inase is not a%oo# i#ea! A#'anta%e) anticoncepti'e!
&crin + >r> anta%onist 3f a'ailable only after cons< %ynecolo%ist!
.ertility will normally not be impaire# with protocols for A , > , *ilm s T&moran# lower ris$ on6>o#%$ins ymphoma! 7yclophosphami#e more thanc&m&lati'e 4%:m2 will impair fertility of both men an# women, with almostin'ariable infertility at c&m&lati'e #oses abo'e 12%:m2 ! *ith more intensi'echemotherapy the ris$ of infertility of co&rse will increase!
3n yo&n% males, sperm preser'ation +cryopreser'ation before startchemotherapy is a possibility! >owe'er, in the %ro&p of boys with a #ia%nosis ofmali%nancy the yiel# is often #isappointin%! 7ons< the fertility center +if presentin yo&r hospital !
.or yo&n% females there is presently no %oo# sol&tion! O'arial tiss&e may becryopreser'e#, an# re6implante# after s&ccessf&l treatment! B&t this is stille perimental with low %ra#e of s&ccess! An# for females with le&$emia orlymphoma it is not possible, beca&se the o'aria are consi#ere# a sanct&ary sitecontainin% mali%nant cells!
3nitial chemotherapy in some chemosensiti'e mali%nancies li$e A , > ,
sometimes A" , an# rarely ne&roblastoma may lea# to rapi# lysis of cells! 'enbefore chemotherapy spontaneo&s t&mor lysis may lea# to problems! Theseproblems are ca&se# by massi'e release of &ric aci#, C an# P, with res<ant
• Precipitation of &ric aci# an# 7a6Phosphate in the $i#neys• 8es<in% in hyper$alemia• >yperphosphatemia• 3mpairment of renal f&nction!
Chec3s• 7lose monitorin% of 9&i# balance e'ery K ho&rs• "onitor bo#y wei%ht an# physical e amination +e#ema- rales-• ab 162 #ayly) a, C, 7a, P, "%, creatinine, &rea, &ric aci# +if rasb&ricase is
%i'en, bloo# t&be on ice, an# cito to lab, beca&se rasb&ricase will#isinte%rate &ric aci# by its enEymatic action e'en in 'itro
Prescriptions
>yperhy#ration +Hliter:m2:#ay, ma G liter:#ay ) to pro'i#e a#e &ate
#i&resis +force# #i&resis an# so pre'ent precipitation in the $i#neys! Allop&rinol! 3t is a anthine o i#ase inhibitor an# th&s bloc$s the pro#&ction
of new &ric aci#! /tart at least 24 ho&rs before chemotherapy to%etherwith hyperhy#ration! <osa%e 2006H00m%:m2:#ay in 26H #oses
3f a'ailable) in cases with hi%h probability of t&mor lysis syn#rome +>8 Amainly ) ricase +8asb&ricase brea$s #own &ric aci#! The &ric aci# le'elwill #rop 'ery &ic$ly! 3t is a 'ery powerf&l inhibitor of the t&mor lysissyn#rome!<osa%e) 1 'ial +N 0!1Gm% per 10$% bo#ywei%ht per #ay, intra'eno&sly!8o&n# o5 at f&ll 'ials +#o not throw away this e pensi'e #r&%; ! >as to %oto%ether with hyperhy#ration! /top if &ric aci# 'al&es are normaliEe#! olon%er than L #ays! "ost fre &ent si#e e5ects) fe'er +; na&sea, 'omitin%,aller%ic reactions!
• A'oi# a##ition of C, 7a or P in the intra'eno&s 9&i#, &nless clinical an#laboratory e'i#ence of hypo6C, hypo67a or hypo6phosphatemia!
General ad1ice for lifestyle to 3eep until @ months afterstop chemo2
• *ash han#s fre &ently, an# learn how to #o this properly!• A'oi# as m&ch as possible contact with lar%e %ro&ps of people!• =o to school or crQche as &s&al, important to feel better;• A'oi# payin% in m&# or san# where animals may ha'e e crete#!• o &ncoo$e# meat, (sh or similar! *ash any fr&it or 'e%etables thoro&%hly!• 7ertainly a'oi# contact with anyone who is fe'erish or ill!• o ris$y sports in case of thrombocytes lower or pre#icte# lower than
G0,000!• 3n case of fe'er + hi%her than HM!G7 once or hi%her than HM!07 twice with 1
ho&r inter'al imme#iately contact the clinic, at all times of #ay an# ni%ht!
<o not wait &ntil ne t mornin%;• "o&th caps are &seless an# sti%matiEin%, so we #isco&ra%e its &se! "o&th
caps may be &se# by persons aro&n# the patient who ha'e a co&%h orapparent airways infection +e'en here, han# washin% is more importantthan mo&th caps
Hand %ashing is of eminent importance, /oth for the patient andfor anyone in close contact %ith the patient2
Use common sense to pre1ent attracting infections fromsurroundings and surrounding persons>
P*!"General2
T%o types of pain+
"ocicepti1e+ somatic, p&lsatin%, 'isceral, well localiEe#, crampin% "europathic+ peripheral +Vincristine ne&ropathy or centrally in#&ce#
+phantom pain
Etiology of pain+
Tumor related !o Tiss&e #ama%eo Bone marrow or bone in(ltrationo 7ompression of or%anso 7ompression of ner'eso 3ncrease# intracranial press&re
• /&bjecti'eo A%e an# psycholo%ical #e'elopmento 7<&ral factorso arlier e perience an# history of pain
• Objecti'eo <epressiono An ietyo Tire#nesso /leeplessness
#elie1ing pain
Pain can be #escribe# as mil#, se'ere or 'ery se'ere! .or many chil#ren the painscale + L or 10 steps with the faces la&%hin% +no pain to cryin% +'ery se'erepain an# all emotions in6between can be of help to #eci#e the se'erity! "othersan# fathers may be able to j&#%e, b&t sometimes they are too a5ecte#themsel'es to be able to score a#e &ately! "ost n&rses will be able to #o that,listen to them;
Proce#&ral pain can be re#&ce# immensely by %oo# information, &iets&rro&n#in%s, %oo# preparation, an# %oo# earlier e perience;;; se of s&rfaceanti6pain meas&res +li#ocaine spray, mla +Nli#ocain R prilocain plaster an#similar may also be helpf&l!
Phase 4+ mild painParacetamol Oral +ta$es 16
2h8ectal +ta$esHh
1061Gm%:$%:#ose206H0m%:$%:#ose
"a K##"a 4##
"a 1,000m%:#ose"a 4,000m%:#ay
Phase 9+ (e1ere pain Trama#ol Oral
8ectal162m%:$%:#ose162m%:$%:#ose
"a 4##"a 4##
o #aily ma
ar%e therape&tic spectr&m) #ose may be increase# &ntil e5ecti'e! 7a&tion)hi%her #oses may in#&ce na&sea an# 'omitin%, so %i'e anti6emetics as nee#e#!7ancer Pain - - - -Phase @+ 1ery se1ere pain "orphine
.entanyl
Oral8ectal3V +or scPlaster
0!Hm%:$%:#ose0!Hm%:$%:#ose
/ee pharma
K##K##
As perbijsl&iter
3ncrease &ntile5ecti'e! oma im&m#ose
• "orphine 4Gm%:#ay e &als abo&t .entanyl plaster12!Gmicro%ram:ho&r
• >ypersensiti'ity reactions before• <r&% has been &se# before• /e'erity of reactions my increase o'er time• Patients with aller%ic constit&tion li$e asthma
Pre'enti'e an# copin% meas&res, prepare an alleric $it that is a'ailableimme#iately)
• Antihistamine +clemastine i!'! for instance, 0!02Gm%:$%:#ose, ma 2m% per#ose
• >y#rocortisone i!'! +4m%:$%:#ose• A#renaline +0!01m%:$% i!'! or i!m! /ol&tion of 1m%:10ml is 0!1m%:ml so
%i'e 0!1ml:$%• a7l 0! I, +rapi# (ll i!'! 20ml:$% an# may be repeate#
Treatment of apparent aller%ic:anaphylactic reaction)
• /top inf&sion of the o5en#in% #r&%!• =i'e antihistaminic• 3f no e5ect in 1G min&tes %i'e hy#rocortisone
Treatment of se'ere anaphylactic reaction) 7hec$ A, B, 7
A) 8espiratory) o ob'io&s &pper airways obstr&ction) %o to B
• /tri#or +hi%her airway obstr&cte# )o =i'e a#renalin i!m!o As$ bystan#er to call intensi'ist teamo O2 100I thro&%h non6rebreathin% mas$o eb&liEe Gml A#renalin sol&tion 1)1000o /e'ere obstr&ction call T specialist for int&bation for cricotomia
• B) 8espiratory) bronchial obstr&ction +wheeEin%, lower airways obstr&ctionif clear %o to 7
o A#renalin i!m!o /alb&tamol neb&liEation +F4y 2!G m%D 4y G!0 m%o O2 100I non rebreathin% mas$ if a'ailable
• 7) circ&latory, no problem) repeat physical e amination, monitoro >ypotension or e'en shoc$)o As$ bystan#er to call reanimation teamo .ill with a7l 0! I 20ml:$% rapi# inf&siono O2 100I by bon rebreathin% mas$o A#renalin i!m!o 3nsert secon# i!'! line or intra6ossal nee#leo 8epeat (llin% with a7l 0! I 20ml:$%o 7hec$ heart rate +physical an#:or monitor an# start reanimation if
no p&lse!
". rechec3 e1ery fe% minutes *, . and C to e1aluate the eBect oftherapy2
• specially in A %l&cocorticoi#s are wi#ely &se#!• An important si#e6e5ect is s&ppression of the hypothalamic6a#renal a is!
This is ca&se# by s&ppression of 78> an# A7T> pro#&ction! 3n the lon% r&n,the a#renal cortisone pro#&cin% cells atrophy, while the al#osteronepro#&ction remains &na5ecte#!
• 3f cortisone pro#&ction is s&Scient &n#er normal con#itions, it may beins&Scient &n#er stress! 3n this case a stress re%imen co&l# an# sho&l# be&se#!
• 3f cortisone pro#&ction is ins&Scient in basal con#ition, replacementtherapy with hy#rocortisone is to be consi#ere#, altho&%h it will f&rthers&ppress the a#renocortical a is!
3n#ication for s&bstit&tion therapy)
• This is only to be consi#ere# in patients with clinical e'i#ence ofa#renocortical ins&Sciency in combination with ser&m cortisol FM0nmol:lmeas&re# at #awn!
• /&bstit&tion therapy is hy#rocortisone 1061G m%:m2:#ay in three #oses#i'i#e# as 2)1)1
• 3f this is nee#e# it sho&l# ne contin&e# an# then tapere#• Taperin%) %i'e only the mornin% #ose of G6L!G m%:m2:#ay for 4 wee$s,
hal'e this #ose for the ne t 4 wee$s an# hal'e a%ain ne t 4 wee$s an#
stop!3n#ication for stress sche#&le)
• Patients who are on maintenance with hy#rocortisone• Patients who ha# %l&cocorticoi# treatment #&rin% at least 2 consec&ti'e
wee$s at a #ose le'el of 1Gm%:m2:#ay cortisone e &i'alent +see below• &i'alent #oses are appro imately)
o <e amethasone 1m%o "ethylpre#nisolone Gm%o Pre#niso+lo ne Lm%o
>y#rocortisone 2Gm%• /tress sche#&le is strati(e# into mo#erate:se'ere:A##ison crisiso "o#erate stress) li$e low %ra#e fe'er, 'iral infection, #entistry!
>y#rocortisone H064G m%:m2:#ay, #i'i#e# into 4 #osesPre#nisone 10 m%:m2:#ay, #i'i#e# into H #oses
o /e'ere stress) li$e hi%her fe'er, witho&t +pre6 shoc$, tra&ma>y#rocortisone G06LG m%:m2:#ay #i'i#e# into 4 #osesPre#nisone 1G m%:m2:#ay #i'i#e# into H #oses
o A##ison crises) si%ns of +pre6 shoc$Bol&s >y#rocortisone i!'!D F1y 2G m%D 16Ky) G0m%D Ky) 100m%!
.ollowe# by) >y#rocortisone 100 m%:m2:#ay i!'! #i'i#e# into 4#oses
Other meas&res accor#in% to clinical state re%ar#in% shoc$!o Anesthesia an# /&r%ical proce#&res)
"inor) an# only nee#e# with pro'en a#renal ins&Sciency)• J&st before anesthesia) Pre#nisone Mm%:m2 i!'!• /ame #ay) another M m%:m2 #i'i#e# into 2 #oses• .irst +sometimes also secon# postoperati'e #ay) 12
m%:m2:#ay #i'i#e# into H #oses"ajor) li$e laparotomy)
• J&st before anesthesia) Pre#nisone 12m%:m2 i!'!• /ame #ay) 12 m%:m2 #i'i#e# into 2 #oses• .irst +maybe also secon# postoperati'e #ay) 1G
m%:m2:#ay #i'i#e# into H #oses
VE"O-OCC'U(!VE !(E*(E 5VO :
!ntroduction
VO< is res< of #ama%e to en#othelial cells in the li'er! The ris$ to #e'elopit is hi%her in persons with a history of hepatitis! 7hemotherapy, an# especially"elphalan, B&s&lphan an# other intensi'e chemotherapy can ca&se it! 3fVincristine is combine# with aEole antif&n%als, it is almost s&re to happen! Beaware;
The diagnosis VO< is a clinical one, base# &pon a trias) the (eattle Criteria+
1! hepatome%aly +often painf&l ,2! hyperbilir&binemia G times normal 'al&e,
H! wei%ht %ain + GI thro&%h ascites! 3f in #o&bt, /= may help, by ascertainin% #iminishe# 9ow or e'en re'erse# 9owin the 'enae portae, with ascites in the ab#ominal ca'ity! A (nal proof may be%aine# thro&%h a li'er biopsy an# Patholo%ic e amination! This may be #one ifthe patient #ies an# the #ia%nosis is not 100I clear! 3t can then be #one witho&ta f&ll post mortem a&topsy! o more problems than Bone "arrow P&nct&re whichmost patients ha'e &n#er%one anyway!
The treatment of VO
•
limit 9&i# inta$e to L06M0 ml:$%:#ay +incl&#in% transf&sions an#me#ication;• .&rosemi#e 1 m%:$% i!'! in 26K #oses per #ay• /ol#acton 26K m%:$% i!'! one #ose per #ay• Ceep thrombocyte co&nt abo'e G0,000• <e(broti#e if a'ailable) 2G m%:$%:#ay i!'! inf&sion s o'er 2 ho&rs• /trict $eepin% of 9&i# balance an# a#aptin% 9&i# inta$e on it!
3n'asi'e infections are common, beca&se the m&cosal barrier is bro$en, an#ne&tropenia is almost always present in cases of se'ere m&cositis! e&tropenicfe'er has to be treate# imme#iately! e&tropenic enterocolitis +typhlitis is a life6threatenin% complication! =&i#elines for ne&tropenic fe'er an# typhlitis area'ailable separately from this #oc&ment!
• probable ne&tropenia of lon%er #&ration + 10 #ays
edication+
• 7e( im• 7ipro9o acin, H0m%:$%:#ay in 2 #oses +ma 1200 m%:#ay• 3traconaEole! K m%:$%:#ay, once #aily as sol&tion +ma 400 m%:#ay
o 3traconaEole sho&l# ne'er be %i'en in sche#&les containin%'incristine! The combination is se'erely hepatoto ic an# ne&roto ican# can be fatal! 3nteraction with other i!'! me#ication is alsopossible since 3traconaEole is a stron% inhibitor of 7@PHA, so many#r&%s which are metaboliEe# by this pathway will reach to ic le'els!
Therefore itraconaEole sho&l# better not be %i'en with anyintra'eno&s chemotherapy!
o .l&conaEole, G m%:$%:#ay once #aily +ma 400m%:#ay also ame#i&m stron% 7@PHA inhibitor with a lon% half life, ca&sin% hi%herle'els of many #r&%s +see pharmacopae !
o 7olistine, L!G m%:$%:#ay in H #oses +ma M00 m%:#ayo Tobramycine, Mm%:$%:#ay in 4 #oses +ma H20 m%:#ayo Amphotercin B, as sol&tion +potion 10 m%:$%:#ay in H #oses +ma
M00 m%:#ay
P"EU OC (T!( P#OPH '*;!( 5PCP:
!ntroduction
Pne&mocystis jiro'eci +formerly pne&mocystis carinii is a f&n%&s! .ormerly it wastho&%ht to be a protoEoan! 3t ca&ses interstitial pne&monia in imm&no#e(cienthosts! Patients at ris$ are all those with prolon%e# lymphocytopenia! 3t &se# to bea fatal complication in patients with A ! B&t it can also occ&r in > , A" an#after lon%er #&ration corticosteroi# me#ication! /ince it was #isco'ere# that low#ose co6trimo aEol is e5ecti'e in pre'ention, P7P pne&monia is rarely seenanymore! 3f co6trim cannot be &se# +aller%y for instance Pentami#ine is alsoe5ecti'e!
edication
• 7o6trimo aEol 1GRH m%:$%:#ay in one #ose on H #ays per wee$! These #aysmay be H consec&ti'e #ays or alternatin% #ays! 3f aller%y, or if bone marrow#epression is a problem +cotrim is mil#ly myelos&ppressi'e pentami#inecan be &se#!
• Pentami#ine i!'! one #ose of 4 m%:$% i!'! e'ery 4 wee$s•
Pentami#ine neb&liEation) M m%:$% e'ery 4 wee$s +ma H00 m%uration of medication
• /tart after in#&ction of A• /top #&rin% ><"T +interaction with renal clearance• 7ontin&e &ntil H months after cessation of maintenance chemotherapy
(T#EPTOCOCCU( V!#! *"( P#OPH '*;!(
!ntroduction
/trep 'iri#ans is a common low patho%en in the oropharyn ! 3n se'erelyne&tropenic patients it can ca&se f&lminant sepsis with A8</! Prophyla is isespecially important in A" patients! "icrobial c<&res to trace antibioticresistant strains is important!
• Penicillin6=) K0,000 3 :$%:#ay i!'! in 4 #oses• .eniticillin) 1G m%:$%:#ay orally in 2 #oses• Amo icillin) 2G m%:$%:#ay in one #ose• 3n cases of resistance to the antibiotics
o Vancomycino Teicoplanino 7laritromycin
uration of medication
/tart after chemotherapy co&rse an# contin&e &ntil *B7 G00 an# A 7200
HE#PE( (! P'E; 5H(V: P#OPH '*;!(
!ndication+
• patients who ha'e ha# stomatitis:m&cositis at prior chemotherapy, an#>/V has been #emonstrate# +if possible !
Varicella oster Vir&s +V V, chic$en po is a relati'ely harmless infection inhealthy chil#ren! 3t is the same 'ir&s that ca&ses >erpes oster! 3n patients on
chemotherapy it is life threatenin%, especially thro&%h V V pne&monitis! Alle5orts sho&l# be #one to pre'ent this 'ir&s %oin% ro&n# the war# +see /tefan&s,
Asian Pac J Cancer Prev. 2010;11(2):289-92 ! Vaccination is possible, b&t has pro'en to be#an%ero&s in imm&no#e(cient patients!
Pre1ention
All members of pe#iatric oncolo%y team nee# to be aware of the #an%er ofchic$en po ! 3t is conta%io&s from a few #ays before the (rst blisters appear &ntilG #ays after , an# as lon% as the blisters are not t&rne# to #ry cr&sts! The stat&sof personnel +imm&ne or not is important to $now! Any person with possible V V+incl&#in% those with herpes Eoster sho&l# be $ept o&t of contact with chil#renon chemotherapy, an# patients with V V infection sho&l# be strictly isolate#! 3fa'ailable, V V hyperimm&ne ser&m sho&l# be &se# to protect non6imm&nepatients who ha# contact with V V!
edication+
• 8ecent contact +F K h )o V V hyperimm&ne ser&m i!m! +or s!c in case of thrombocytopeniao Valacyclo'ir H0 m%:$%:#ay orally in 2 #oses
• 7ontact more than K ho&rs a%o)o Valacyclo'ir K0 m%:$%:#ay in 2 #oses +"a H,000 m%:#ay
• <&ration) &ntil 2M #ays after contact!• 3f clinical symptoms +e anthema, blisters still occ&r
o Acyclo'ir H0 m%:$%:#ay in H## i!'!o Valacyclo'ir 0 m%:$%:#ay orally in H #oses +ma H,000 m%:#ayo Postpone chemotherapy &ntil s$in rash has cleare# +cr&sts may still
be present
V*CC!"*T!O"
The &s&al 'accinations ha'e to be postpone# #&rin% chemotherapy! One the onesi#e beca&se it is #o&btf&l whether they will res< in imm&nity in 'iew of theimm&nos&ppresse# state, on the other han# beca&se 'accination with li'eatten&ate# strains may still ca&se se'ere #isease! This happene# for instancewith Varicella oster 'accination!
The 'accination pro%ram howe'er has to be pic$e# &p a%ain H months after stopchemotherapy! /o all 'accinations that ha'e been s$ippe# sho&l# then be %i'en!
A special sit&ation may occ&r with 'ery intensi'e chemotherapy, as in+a&tolo%o&s stem cell +re inf&sion! Thes patients nee# re6'accination e'en if theyrecei'e# all 'accinations alrea#y as sche#&le#!
All bloo# pro#&cts sho&l# be (ltere# to limit the possibility of 'iral infections! 3fpossible, irra#iate# pro#&cts sho&l# be &se#, in cases of intensi'e myeloablati'etherapy +stem cell transplantation b&t also in case of family #onors +; ! Patientswith +cell6me#iate#, T6cell imm&no#e(ciency sho&l# also ha'e the bloo#pro#&cts irra#iate# to pre'ent =raft6'ers&s6>ost <isease +='>< !
Erythrocyte concentrates, Pac3ed #ed Cells 5P#C:
!ndication+
• 7linical e'i#ence of anemia• Transf&sion limits) see below• e'er %i'e &nnecessary transf&sions• Always or#er ba%s so that nothin% has to be #iscar#e#
o .or instance if patient nee#s H00ml, an# a ba% is 2G0 ml) or#er oneba%, not two!
Transfusion limits
• 3n a patient in %oo# con#ition, no fe'er, no infection) >b F K!0%:#l +4 mmol:l
• 3n a patient in %oo# con#ition b&t before a chemo co&rse) >b F L!G%:#l +G mmol:l
•
3n a sic$ patient, s&spicion of sepsis) >b F !0 %:#l +Kmmol:l
Ho% much and ho% fast
• 3f chronic, #&rin% chemotherapy) 1061G ml:$% +ro&n# o5 at the nearestlower n&mber of ba%s in 46G ho&rs, chil#ren 40 $%) 2 ba%s only!
• 3f bloo# loss +li$e %astro6intestinal blee#in% ) start with 1061G ml:$% an#inf&se as &ic$ly as possible! Or#er more ba%s if blee#in% is still inpro%ress! 8emember that =3 bloo# loss can be massi'e, witho&t m&chbloo# appearin% in the stools;
TH#O .OC TE T#*"($U(!O"(
!ndications
• 3f manifest blee#in% in thrombocytopenic patients• 3f a s&r%ical proce#&re or P is planne# in thrombocytopenic patients
Transfusion limits
• Prophylactic +A" , sepsis F 20,000• Prophylactic insertion =T F 20,000• Prophylactic) (rst P in A , A" F G0,000• Prophylactic later P s F 20,000
• Prophylactic +se'ere m&cositis F G0,000• Therape&tic, acti'e blee#in% F G0,000• 3ntracranial blee#in% F 100,000
Ho% much and ho% fast
• One #onor &nit per 10$%, fast inf&sion &nless circ&latory o'erloa#threatens
• e'er throw away thrombocyte s&spensions +or any bloo# pro#&ct for thatmatter &nless there is a transf&sion reaction! 3n that case stop imme#iatelan# sen# ba% bac$ to bloo# transf&sion ser'ice for analysis +they may as$a bloo# sample frm the patient to analyEe antibo#ies
G#*"U'OC TE T#*"($U(!O"(
/till e perimental an# not yet e'i#ence base#! 8is$s are consi#erable
G-C($ 5 "EUPOGE", $!'G#*(T! , ETC:
"ay be &se# in life6threatenin% infections in ne&tropenic patients, sepsis,f&n%al p&lmonary infections +Asper%ill&s
8an#omiEe# blin#e# placebo controlle# trial in /t6J&#e s /A showe# abo&t24 ho&rs earlier appearance of ne&trophils in the circ&lation, b&t no e5ecton morbi#ity or mortality whatsoe'er! +P&i 7>) n%l J "e#!1 LDHHK)1LM16L =67/. may increase the ris$ of secon#ary A" +8ellin%"V) Bloo#! 200HD101)HMK26L
3t is e pensi'e, parenteral a#ministration necessary!
Anthracyclines are the most car#ioto ic #r&%s! 7ombination with ra#iotherapyincreases this problem! To icity may alrea#y appear #&rin% therapy, b&t it may#e'elop years later! 7ar#ioto icity is #ose6relate#, b&t yo&n%er chil#ren an#females tolerate smaller #oses, an# there is probably interaction with some 'iralinfections too!
"eas&res to limit anthracycline car#ioto icity ha'e trie#) inf&sion o'er lon%erperio#s +1624 ho&rs , an# a##ition of a chemoprotector +#e raEo one , b&t noneof these are ro&tine! 3nf&sion o'er at least 1 ho&r is a#'ocate#, if only to #etectearlier e tra'asation, an# so limit 'asc&litis an# necrosis!
arly #ia%nosis of incipient car#iac #ama%e is important, it allows for pre'entin%
f&rther #eterioration by stoppin% the &se of anthracyclines! 3t is a %oo# i#ea toha'e a car#iac /= meas&rin% at least the shortenin% fraction +/. an# repeatthis when a certain threshol# is passe#! .or #o or&bicin this is a lifetimec&m&lati'e #ose of 240m%:m2!
To chec$ for late e5ects, many clinics ha'e a policy to repeat car#iac /=ann&ally! >owe'er, not m&ch can be #one if to icity appears! >a'in% sai# this, ofco&rse if clinical si%ns of heart fail&re occ&r, certainly #ia%nostic tests arin#icate#!
"EU#OTO;!C!T
Complications from disease
e&rolo%ical symptoms often occ&r in brain t&mor patients an# sometimes inA ! A s &int in a patient with A , or any cranial ner'e palsy is ta$en ase'i#ence of menin%eal in'ol'ement an# nee#s treatment a#aptation!
7on'&lsions +(ts may res< from the t&mor itself or from infections an# frommetabolic #ist&rbances!
"yelocompression from ne&roblastoma +#&mbbell t&mors , chloroma, or A
#eposits are a me#ical emer%ency! <e amethasone may help b&t is often notf&lly e5ecti'e! e&ros&r%ical a#'ice an# e'ent&al treatment is man#atory!
7erebro'asc&lar complications in A" "H is also a me#ical &r%ency!
Complications from treatment
Ac&te ne&rolo%ical symptoms may occ&r after intrathecal a#ministration as wellas after chemotherapy with A8A67, 3fosfami#e an# "T ! ower ser&m alb&minmay increase the ris$ beca&se ther is more free #r&% in the circ&lation+3fosfami#e for instance !
7erebro'asc&lar inci#ents may occ&r after 6Aspara%inase therapy, infections an##i5&se intra'asc&lar coa%&lation +<37
e&coencephalopathy has been #escribe# after hi%h #ose A8A67m hi%h #ose "Tan# after intrathecal therapy!
7orticosteroi#s, an# especially #e amethasone ca&se #ehy#ration of brain tiss&e+that s why it is e5ecti'e in cerebral e#ema , an# this is sometimes interprete#
by ra#iolo%ists as U brain atrophy ! 3t is howe'er re'ersible an# lea'es no tracesafter the steroi# treatment has en#e#! /teroi#s are also responsible forpsycholo%ic alterations:#ist&rbances) #epression, (ts of an%er, sleeplessnessetcetera!
OTOTO;!C!T
This is partic&larly a problem after treatment with 7isplatin! The hi%her tones area5ecte# (rst! /ymptoms may increase o'er the years e'en if no more cisplatin is%i'en! 7ombination with ra#iotherapy on the brain an# especially on the innerear will increase the ris$ of ototo icity!
Therefore a&#iolo%ic chec$ is a#'ise# before start treatment with platincontainin% re%imens! The a&#io%rams sho&l# be repeate# j&st before e'eryco&rse of chemotherapy! 7hec$s after stop chemotherapy is also 'al&able, somepatients nee# hearin% ai#s later!
*V*(CU'*# "EC#O(!( O$ .O"E 5*V":
7orticosteroi#s, in combination with other #r&%s +"T is incriminate# are thec&lprit! This is partic&larly a problem for ol#er chil#ren +a few percent an# yo&n%a#<s +&p to 20I ! "ost a5ecte#, or at least most c&mbersome, are the bi% joint
of the lower e tremities) hip an# $nee! 3f it occ&rs +pain, limitation of motion thebest #ia%nostic test, after physical e amination, is an "83 which will show atypical pattern! Plain 6rays may also show #ama%e in more a#'ance# cases!"eas&res to re#&ce the pain an# the possibility of permanent joint #ama%e arepre'entin% press&re on the a5ecte# joints, splints, b&t with passi'e motion+physiotherapy an# limitin% the steroi# e pos&re! .or instance by s$ippin% the#e a or pre#nsone p&lses in maintenance therapy an# %i'in% contin&o&s"T RK"P instea#!
Adapted from VUmc Authors Smits and Kors, 2008, revised 2011